Resources Archive - WuXi Biology

Integrated Strategies for KRAS Inhibitor Development

As one of the most frequently mutated oncogenes in human cancers, KRAS was long considered an “undruggable” target. Recent landmark...

Development of the Venetoclax-Resistant AML Model

Acute myeloid leukemia (AML) remains a highly aggressive hematologic malignancy, responsible for over 100,000 deaths globally each year. The approval...

Biophysical Methods for Rapid Screening and Hit Validation

At DDC 2026, WuXi AppTec presented a poster showcasing our integrated discovery platform designed to accelerate the identification and validation...

Spectral Shift for Ultra-High-Throughput Binding Assays

High-throughput screening (HTS) remains critical for early drug discovery, yet traditional biochemical assays and specialized techniques such as affinity selection...

Targeted In Vitro Pharmacology for GIPR/GLP-1R/GCGR

Current weight-loss therapies primarily act on the gut–brain axis, often using incretin-based approaches such as GIP, GLP-1, and glucagon receptor...

DEL and Display Technologies Empower Discovery of Peptide Drugs

In recent years, peptide-based therapeutics have emerged as a significant class of drugs in the pharmaceutical landscape, offering numerous advantages,...

D2B: Direct-to-Biology Platform

Looking for a solution to accelerate your drug discovery processes? WuXi AppTec’s integrated Direct-to-Biology (D2B) platform is a cost-effective and...

AACR 2026 Posters: Sneak Peek

AACR 2026 Posters | Sneak Peek The Annual Meeting of the American Association for Cancer Research (AACR) will be held...

Short-Term Mouse Model to Accelerate SLE Drug Discovery

Accelerating SLE Drug Discovery: A Short-Term BM12-Induced Mouse Model for Efficient Drug Screening Systemic lupus erythematosus (SLE) is a chronic...

Knowledge Library